Gender
All
Age Group
18 Years and up
Accepting Healthy Volunteers
No
Inclusion Criteria
- Confirmed diagnosis of symptomatic multiple myeloma (MM).
- Eastern Cooperative Oncology Group performance status (ECOG) score of 0, 1, or 2.
- Received 3 to 6 cycles of an induction therapy that includes a proteasome inhibitor
(PI) and immunomodulatory (IMiD) [eg, bortezomib thalidomide and dexamethasone
(VTd), lenalidomide, bortezomib and dexamethasone (RVd)] with or without a CD38
monoclonal antibody, daratumumab + bortezomib/thalidomide/dexamethasone [D-VTd] and
daratumumab + bortezomib/ lenalidomide/dexamethasone [D-VRd]), or VCd / daratumumab
+ bortezomib/cyclophosphamide/dexamethasone [D-VCd], and followed by a single or
tandem autologous stem cell transplantation (ASCT). Post-stem cell transplant
consolidation is permitted.
- Participants within 12 months (single transplant) or 15 months (tandem transplant)
from initiation of induction therapy who achieved at least a partial response (PR)
after autologous stem cell transplantation (ASCT) with or without consolidation,
according to International Myeloma Working Group (IMWG 2016) criteria.
Exclusion Criteria
- Progressive disease or clinical relapse (as defined by IMWG response criteria)
following ASCT with or without consolidation or is not responsive to primary
therapy.
- Smoldering myeloma, solitary plasmacytoma or nonsecretory myeloma.
- Known central nervous system/meningeal involvement of MM.
- Prior history of malignancies, other than MM, unless the participant has been free
of the disease for ≥ 5 years.
- Other protocol-defined Inclusion/Exclusion criteria apply.